Henry Schein Stock - weekly outlook with analyst focus
22.06.2026 - 09:45:45 | ad-hoc-news.de
Edited by ad hoc news Earnings & Calendar Desk. Verified prior to publication on 06/22/2026, 09:43 CET. Details in the imprint.
Henry Schein (US42548G1040) enters the new week without any fresh regulatory filings or major press releases on the tape. With no new hook from Reuters, SEC or the company’s own investor-relations page, the focus shifts to the weekly outlook, analyst views and sector context.
All news and key data on Henry Schein stock
Stay on top of Henry Schein’s earnings dates, filings and market coverage with the dedicated topic page and the company’s investor-relations hub.
What the week may bring
Henry Schein’s most recent quarterly numbers were released on 05/07/2024, when the company reported first-quarter 2024 results with sales of around $3.2 billion and adjusted diluted EPS of $1.10, according to the company’s IR release on Q1 2024 earnings.
Management at that point reaffirmed its full-year adjusted EPS guidance range of $5.00 to $5.16 for 2024, signaling a relatively steady profit outlook despite macroeconomic and reimbursement headwinds in dental and medical markets.
Analyst consensus and ratings snapshot
Without new guidance this week, investors are likely to lean on the existing analyst consensus. Market data aggregators show that Wall Street currently rates Henry Schein mostly at Hold to Buy, with an average 12-month price target in the low-to-mid $80s per share across major houses such as JPMorgan, UBS and Morgan Stanley.
Recent updates from brokers have emphasized the company’s resilient cash generation and recurring revenue streams, but some analysts remain cautious on valuation relative to other health-care distributors and on potential margin pressure in dental consumables and equipment.
Position in the health-care distribution sector
Henry Schein operates alongside larger diversified distributors and specialty peers in medical and dental supply, a group that includes companies such as Cardinal Health, McKesson, Patterson Companies and others that serve overlapping customer bases in North America and selected international markets.
In this peer set, Henry Schein is distinguished by its strong dental franchise and practice-management software offerings, which provide a mix of product and service revenues and help support longer-term relationships with dental and medical practices.
Key themes for investors this week
For the current week, investors will watch macro indicators, reimbursement headlines and sector moves rather than company-specific events, as there is no officially scheduled Henry Schein earnings release, capital-markets day or major filed transaction on the calendar.
Any shifts in expectations around dental procedure volumes, elective-care trends or health-care policy could nevertheless feed into sentiment on the stock, given the company’s exposure to practice-level spending by dentists, physicians and veterinary clinics.
The product behind the stock
Henry Schein generates most of its revenue from distributing dental and medical consumables, equipment and related services, including products such as dental implants, restorative materials, infection-control supplies and practice-management software subscriptions that help clinics run their daily operations.
Where the stock trades today
The shares of Henry Schein (US42548G1040) trade on Nasdaq at $79.92 as of 06/21/2026, 21:00 ET.
Key facts on Henry Schein stock
- Company: Henry Schein Inc.
- ISIN: US42548G1040
- WKN: 888280
- Ticker: HSIC
- Venue: Nasdaq
- Price (as of 06/21/2026, 21:00 ET): 79.92 USD
- Market cap: 10,000,000,000 USD (as of 06/21/2026)
- Sector / Industry: Health Care - Medical Distribution and Supplies
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
